The following is a statement from the Hematology/Oncology Pharmacy Association:
In light of recent discussions surrounding the potential use of leucovorin in the treatment of autism, we want to reaffirm that leucovorin is a well-established, essential component of cancer therapy. It plays a critical role in protecting patients receiving high-dose methotrexate for certain leukemias and lymphomas, and it enhances the effectiveness of fluorouracil in the treatment of gastrointestinal cancers.
We urge healthcare providers and patients to make treatment decisions based on rigorous, evidence-based research. A surge in demand for leucovorin driven by unproven claims could lead to supply shortages and put people with cancer—who depend on this medication for survival—at serious risk.
It is vital that the medical community and patient advocates continue to follow sound science and peer-reviewed data in guiding the use of leucovorin, ensuring that access remains available for those who need it most.
